Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/26350112http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/26350112http://www.w3.org/2000/01/rdf-schema#comment"

Objective

The cancer/testis (C/T) antigen Transmembrane Phosphatase with TEnsin homology (TPTE) is aberrantly expressed in many tumors including lung cancer. In the present study, we analyzed TPTE-auto-antibodies in lung cancer patients.

Methods

Using a crude-lysate ELISA, we analyzed a large cohort of 307 sera from lung cancer patients and 47 healthy donors for TPTE-specific autoantibodies. Sero-reactivity was correlated with clinical parameters and patients' survival.

Results

TPTE-specific antibodies were detected in 41 of 307 (13.4%) sera from lung cancer patients. Based on an optimal cut-off value calculated by ROC curve analysis sensitivity for diagnosing lung cancer was 52% and specificity was 72%. TPTE sero-positivity was not associated with tumor stage, tumor histology, gender or age. Multivariate analysis indicated that TPTE sero-positivity is associated with prolonged survival in patients with lung cancer, but established prognostic factors for survival prediction such as stage and histology remain indispensable.

Conclusion

Autoantibodies against TPTE occur spontaneously in lung cancer patients. TPTE sero-reactivity has moderate sensitivity and specificity for diagnosing lung cancer and is a positive prognostic marker."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.org/dc/terms/identifier"doi:10.1016/j.lungcan.2015.07.012"xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Simon P."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Kuemmel A."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Sahin U."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Tureci O."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Sebastian M."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Buhl R."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Elsasser A."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Luxemburger U."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Breitkreuz A."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Rohlig J."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/author"Schmidt L.H."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/name"Lung Cancer"xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/pages"334-341"xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/title"Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE)."xsd:string
http://purl.uniprot.org/citations/26350112http://purl.uniprot.org/core/volume"90"xsd:string
http://purl.uniprot.org/citations/26350112http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/26350112
http://purl.uniprot.org/citations/26350112http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/26350112
http://purl.uniprot.org/uniprot/#_P56180-mappedCitation-26350112http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26350112
http://purl.uniprot.org/uniprot/P56180http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/26350112